Gilead Sciences and Arcus Biosciences report cancer trial data

Gilead Sciences and Arcus Biosciences have reported initial assessment data from Arm A1 of the EDGE-Gastric clinical trial of domvanalimab in combination with zimberelimab and chemotherapy.

The international, multi-arm Phase II study is designed to assess the efficacy and safety of various combinations of domvanalimab and zimberelimab for treating upper gastrointestinal (GI) cancers.